<DOC>
	<DOCNO>NCT01938495</DOCNO>
	<brief_summary>The study conduct determine DPS treatment people ALS hypoventilation associate improved survival diaphragm function . The primary objective study conduct multi-center , randomize control clinical trial compare standard care ( control ) diaphragm stimulator treatment NeuRx® Diaphragm Pacing System™ ( DPS ) respect survival . The secondary objective study conduct multi-center , randomize control clinical trial compare standard care treatment ( control ) DPS ALS subject hypoventilation .</brief_summary>
	<brief_title>Diaphragm Pacing System ( DPS ) In Participants With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>The study randomize control study compare standard care ( control ) DPS ( diaphragm stimulator name The NeuRx® Diaphragm Pacing System™ ) . Although remains uncertain DPS efficacious ALS subject , give preliminary study perform device manufacturer , receive FDA humanitarian device exemption ( HDE ) approval humanitarian use device ( HUD ) . This study utilize 2:1 randomization schedule eligible ALS subject 2/3 chance receive DPS 1/3 chance standard care ( control ) treatment . The NeuRx® Diaphragm Pacing System™ ( DPS ) four channel , implant percutaneous diaphragm muscle stimulation system . Under general anesthesia , intramuscular electrode laparoscopically implant diaphragm . The end implant electrode tunnel subcutaneously exit site chest abdominal wall connect external stimulator .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1 . Age 21 year old . 2 . Sporadic familial ALS diagnose definite , probable possible ALS define revise El Escorial criterion . 3 . Evidence hypoventilation Screening least one following : 1 . Maximal static inspiratory pressure ( MIP ) &lt; 60 cm H20 . 2 . Upright supine force vital capacity ( FVC ) &lt; 50 % predicted gender , age , height . 4 . A phrenic nerve potential recordable bilaterally . 5 . Subjects must take riluzole least 30 day , stable dose riluzole least 30 day , prior randomization ( riluzolenaïve subject permit study ) . 6 . Capable provide informed consent follow trial procedure . 7 . Geographically accessible site . 8 . Negative urine pregnancy test Screening woman child bear potential ( WOCBP ) . ( Women postmenopausal hysterectomy deem child bear potential ) . 9 . Women child bear potential must use adequate form contraception : abstinence , hormonal contraception ( oral contraception , implanted contraception , inject contraception hormonal ( patch contraceptive ring , example ) contraception ) , intrauterine device ( IUD ) place ≥ 3 month , barrier method conjunction spermicide , another adequate method . 1 . Upright force vital capacity ( FVC ) ≤ 45 % predicted gender , age , height . 2 . Any prior use noninvasive ventilation ( NIV ) outside sleep ( nighttime nap ) . 3 . Any pulmonary cardiac disorder medical disorder would contraindication general anesthesia DPS hardware implantation chest . 4 . Implanted electrical device pacemaker cardiac defibrillator . 5 . Known diaphragm abnormality hiatal hernia paraesophageal hernia abdominal content thoracic cavity . 6 . Participation another treatment research study people ALS . 7 . Exposure agent currently investigation treatment people ALS ( offlabel use investigational ) within 30 day Screening Visit . 8 . Clinically significant history unstable severe cardiac , oncologic , hepatic , psychiatric , renal disease , medically significant illness . 9 . Pregnant woman woman currently breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ALS</keyword>
	<keyword>DPS</keyword>
	<keyword>Diaphragm Pacing</keyword>
</DOC>